Failure to Recoup R&D Investment and Delays in Obtaining Approval
First written in FY2018. 3 of 4 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2018: 1 of 6 companies on the "Worse" side.
4 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「In bringing newly developed products to market, we address approval procedures and other matters based on detailed plans. However, if our group or its partner manufacturers are unable to obtain approvals as planned, the supply of products to the market may be delayed, potentially affecting our group's business, operating results and financial condition.」
The risks of failing to recover R&D investments and delays in obtaining approvals, and the responses through marketing, information sharing and development checks, are being reconfirmed. - FY2021RestatedAnnual report
「If excessive upfront investment is made through these activities, it could affect the Group's operating results and other matters.」
The risk of failing to recover R&D investments and delays in obtaining approvals is being reconfirmed. - FY2019RestatedAnnual report
「If excessive upfront investment is made through these activities, it could affect the Group's operating results and other matters.」
The risk of failing to recover R&D investments and delays in obtaining approvals is being reconfirmed. - FY2018First statedAnnual report
「If excessive upfront investment is made through these activities, it could affect the Group's operating results and other matters.」
The company recognizes the possibility that R&D may not generate earnings and that delays in obtaining approvals may delay the supply of products to the market.